Alvotech · NASDAQ:ALVO
Alvotech — Q2 2025 Earnings Presentation
12 slides from Alvotech's earnings presentation, Aug 14, 2025
Slide 1: Q2 2025 Earnings and Business Update
Q2 2025 Earnings and Business Update August 14, 2025
Slide 2: Disclaimer
Disclaimer This presentation (“Presentation”) does not contain or factors which could cause actual results to differ materially products; (16) the outcome of ongoing and future litigation measures not presented in accordance with International constitute an offer to sell, a solicitation of an offer
Slide 3: Agenda
Agenda RÓBERT WESSMAN Chairman and Chief Executive Officer LINDA JÓNSDÓTTIR Chief Financial Officer 1 KEY HIGHLIGHTS ANIL OKAY Chief Commercial Officer 2 FINANCIAL UPDATE JOEL MORALES Outgoing CFO 3 Q&A BENEDIKT STEFÁNSSON VP of IR and Global Communication
Slide 4: Róbert Wessman
Róbert Wessman Chairman and Chief Executive Officer
Slide 5: Strong Growth Momentum
Strong Growth Momentum STRONG FINANCIAL ROBUST PERFORMANCE IN PARTNERSHIP AGREEMENTS PERFORMANCE MAJOR MARKETS AND ACQUISITIONS Over 200% increase in product Biosimilar to Humira® continues gaining Expanded partnership with Advanz revenues compared to H1 last market share in Europe and has 2nd to in
Slide 6: Marketed Products
Marketed Products Biosimilar to Humira® Biosimilar to Stelara® Formulary exclusion for Humira® UZPRUVO® with highest or second highest market share originator is accelerating conversions in for Stelara® biosimilars in each market launched U.S. to biosimilars Conversion of Stelara® market to biosimil
Slide 7: Linda Jónsdottir
Linda Jónsdottir Chief Financial Officer
Slide 8: Strong Product Revenue growth driving EBITDA
Strong Product Revenue growth driving EBITDA Strong Product Revenue growth driven by: Continued momentum with Humira® biosimilar after US launch in in Q2 ADJUSTED 2024 and increased EU sales in the period. RESULTS CHANGE Growing sales of biosimilar to STELARA® in EU after launch in Q3’24 and USD Mil
Slide 9: Cash & Liquidity
Cash & Liquidity Strong cash flow from operations of $77 million, improvement of $161 million year-on-year Cash and cash equivalents of $151 million as of June 30, positively impacted by operational performance and proceeds from Swedish private placement Substantial improvements in capital structure
Slide 10: Appendix
A alvotech Appendix
Slide 11: Reported to Adjusted Reconciliation
Reported to Adjusted Reconciliation H1 2025 H1 2024 H1 2025 Adjustment Entries Adjustment Adjustment $ millions Reported Adjusted Reported Adjusted Cost of Product Revenue − $1.3m charge related to long-term incentive plan Entries Entries Product Revenue 204.7 - 204.7 65.9 - 65.9 − $0.8m charge rela
Slide 12: Additional information
Additional investors.alvotech.com investors.alvotech.com alvotech.com information alvotech.com alvotech.is alvotech.is alvotech.ir@alvotech.com alvotech.ir@alvotech.com